

Press Release



Notice of Revisions to the Forecast of Consolidated Financial Results for FY2023

TOKYO, September 25, 2023 – ASKA Pharmaceutical Holdings Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Takashi Yamaguchi) announced that the Company has resolved at the board meeting held today to revise the forecast of the consolidated financial results for the year ending in March 2024 announced on May 11, 2023, as follows.

1. Revisions to the Forecast of Consolidated Financial Results

(1) Forecasts of Consolidated Financial Results for FY2023

(April 1, 2023 to March 31, 2024)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Earnings per share
Previous forecast (A)	Millions of yen 62,000	Millions of yen 5,400	Millions of yen 5,500	Millions of yen 4,400	Yen 155.81
Revised forecast (B)	62,000	5,400	5,500	6,200	219.18
Change (B-A)	0	0	0	1,800	
Rate of change (%)	0	0	0	40.9%	
(Reference) Results for the previous fiscal year FY2022	60,461	5,108	5,232	4,238	150.08

(2) Reason for the Revisions

The Company is in the process of reducing its cross-shareholdings with the target of reducing its cross-shareholdings to less than 20% of consolidated net assets. As part of this effort, the Company plans to sell listed securities held by its subsidiary ASKA Pharmaceutical Co., Ltd. during the second to third quarter of the current fiscal year. It expects to record a gain on sales of investment securities of approximately 2,700 million yen as an extraordinary gain, based on current estimates. Accordingly, profit attributable to owners of parent is revised to 6,200 million yen, 1,800 million yen higher than the previously announced figure.

(NOTE) The above forecast has been prepared based on information available as of the announcement date and is subject to various uncertainties. As a result, actual results may differ from this forecast.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp